<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002822</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064998</org_study_id>
    <secondary_id>MRC-LU21</secondary_id>
    <secondary_id>EU-96019</secondary_id>
    <nct_id>NCT00002822</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer</brief_title>
  <official_title>RANDOMISED CLINICAL TRIAL OF IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE WITH MID-CYCLE VINCRISTINE (VICE) VERSUS STANDARD PRACTICE CHEMOTHERAPY IN PATIENTS WITH LIMITED STAGE SMALL CELL LUNG CANCER (SCLC) AND GOOD PERFORMANCE STATUS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug is a way to kill more tumor cells.&#xD;
      Combining radiation therapy with chemotherapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effect of two combination chemotherapy&#xD;
      regimens followed by radiation therapy in treating patients with small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the survival rate in patients with newly diagnosed small cell lung cancer and&#xD;
           good performance status treated with an intensive regimen of&#xD;
           ifosfamide/carboplatin/etoposide with mid-cycle vincristine (VICE) vs. standard&#xD;
           chemotherapy followed, as feasible, by thoracic radiotherapy.&#xD;
&#xD;
        -  Compare the adverse effects of treatment and quality of life (including psychological&#xD;
           distress, physical status, and functional status and global quality of life) in these&#xD;
           patients.&#xD;
&#xD;
        -  Compare the Rotterdam Symptom Checklist vs. the EORTC QLQ-C30 and LC13 quality-of-life&#xD;
           questionnaires in relation to compliance and ability to detect differences between&#xD;
           treatments.&#xD;
&#xD;
      OUTLINE: This is a randomized study.&#xD;
&#xD;
      The first group receives standard combination chemotherapy with&#xD;
      doxorubicin/cyclophosphamide/etoposide (ACE) or cisplatin/etoposide (PE) every 3 weeks for 6&#xD;
      courses.&#xD;
&#xD;
      The second group receives intensive combination chemotherapy with&#xD;
      carboplatin/ifosfamide/etoposide on days 1-3 with vincristine on day 14 (VICE). Courses&#xD;
      repeat every 4 weeks for 6 courses.&#xD;
&#xD;
      Patients in both groups are considered for thoracic radiotherapy beginning 4-5 weeks after&#xD;
      the first day of the last course of chemotherapy.&#xD;
&#xD;
      Concurrent prophylactic antibiotics should be given. Patients who relapse may receive further&#xD;
      treatment at the clinician's option.&#xD;
&#xD;
      Patients are followed monthly for 6 months, every 2 months for up to 1 year, every 3 months&#xD;
      for up to 2 years, every 6 months for 5 years, and annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 400 patients will be entered over 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1996</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mesna</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Microscopically proven small cell lung cancer&#xD;
&#xD;
               -  Diagnosis based on bronchial, mediastinal, pleural, lung, or lymph node biopsy,&#xD;
                  sputum cytology, or bronchial brushing or fine needle aspirate cytology&#xD;
&#xD;
               -  No pleural fluid cytology&#xD;
&#xD;
          -  No prior therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC more than 3,000&#xD;
&#xD;
          -  ANC more than 1,500&#xD;
&#xD;
          -  Platelets more than 100,000&#xD;
&#xD;
        Hepatic/Renal:&#xD;
&#xD;
          -  Alkaline phosphatase, aminotransferase, sodium, and LDH normal or no more than 1 of&#xD;
             them abnormal&#xD;
&#xD;
          -  Creatinine or urea normal&#xD;
&#xD;
          -  Creatinine clearance or GFR more than 65 mL/min&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No clinical evidence of infection&#xD;
&#xD;
          -  No prior or concurrent malignancy that interferes with protocol treatments or&#xD;
             comparisons&#xD;
&#xD;
          -  No other condition that contraindicates treatment&#xD;
&#xD;
          -  Willing and able to complete quality-of-life questionnaires&#xD;
&#xD;
               -  Hospital Anxiety and Depression Scale, Rotterdam Symptom Checklist, and EORTC&#xD;
                  questionnaires completed prior to randomization&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J. Girling, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical Research Council</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Research Council Clinical Trials Unit</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW1 2DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Thatcher N, Qian W, Clark PI, Hopwood P, Sambrook RJ, Owens R, Stephens RJ, Girling DJ. Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial. J Clin Oncol. 2005 Nov 20;23(33):8371-9. doi: 10.1200/JCO.2004.00.9969.</citation>
    <PMID>16293867</PMID>
  </results_reference>
  <verification_date>December 2000</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 15, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2003</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>limited stage small cell lung cancer</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

